Crinetics Pharmaceuticals (CRNX) Q4 2025 earnings review
First Commercial Revenue Validates Pipeline, But Cash Burn Accelerates
Crinetics successfully transitioned to a commercial-stage company, reporting a reversing trend in top-line growth with $5.4M in Q4 net product revenue from the launch of PALSONIFY. Early launch metrics are highly encouraging, with over 200 enrollment forms and broad adoption across both community and specialized settings. However, building out a commercial organization and aggressively advancing multiple Phase 3 trials is expensive. Operating expenses surged 47% YoY in Q4, and guidance points to accelerating spending in FY26. Bolstered by a $380M capital raise in January, the company's $1.4B pro-forma cash pile provides the necessary runway to absorb this burn while pushing its endocrinology pipeline forward.
🐂 Bull Case
PALSONIFY generated $5.4M in its first partial quarter with over 125 unique prescribers. A 50/50 split between community endocrinologists and pituitary centers proves the once-daily oral value proposition has broad appeal beyond specialized academic hubs.
Crinetics is no longer a single-asset story. The company initiated three pivotal trials in late 2025 (CAREFNDR for carcinoid syndrome, plus adult and pediatric CAH trials for atumelnant), vastly expanding its total addressable market.
🐻 Bear Case
While 200+ enrollment forms indicate strong demand, 50% of dispensed bottles were through the un-reimbursed 'Quickstart' program. Until these patients secure prior authorizations, a large portion of the prescription volume will not translate to revenue.
Selling, general and administrative expenses nearly doubled YoY in Q4 to $53.7M. With FY26 GAAP OpEx guided to a midpoint of $625M, the company must flawlessly execute the PALSONIFY launch to justify the expanding cost structure.
⚖️ Verdict: 🟢
Bullish. The PALSONIFY launch is demonstrating excellent early traction, and the CHMP positive opinion de-risks European expansion. While OpEx is high, a $1.4B pro-forma cash balance completely removes near-term financing overhangs, allowing management to execute purely on fundamentals.
Key Themes
PALSONIFY Launch Adoption Accelerating
The Q4 launch in the U.S. surpassed expectations with $5.4M in net product revenue. The underlying metrics are even stronger: >200 enrollment forms and 81% of prior authorizations secured for a duration of 300 days or more. This indicates that payers are not putting up restrictive roadblocks and are recognizing the value of the oral therapy over existing injectables.
Atumelnant Data Validates CAH Mechanism
Phase 2 open-label data for atumelnant in congenital adrenal hyperplasia (CAH) showed a stable, dose-dependent response. In Cohort 4, 88% of participants successfully reduced glucocorticoid doses to physiologic replacement levels by week 12 while maintaining 67% mean androstenedione (A4) reductions. This validates the drug's mechanism to decouple androgen control from steroid reliance, a massive clinical innovation for this patient population.
European Expansion De-Risked
The CHMP adopted a positive opinion recommending the marketing authorization of PALSONIFY in Europe. With the formal European Commission approval expected shortly, Crinetics is positioned to tap into an international market that relies heavily on a few concentrated centers of excellence, streamlining the future European sales effort.
Commercial Build-out Crushing Near-Term Margins
SG&A expenses grew from $28.2M in 24Q4 to $53.7M in 25Q4. While expected during a launch, the absolute level of spend is massive relative to current revenue. The company is investing heavily in field force and corporate functions. If PALSONIFY uptake decelerates after the initial wave of easy 'switch' patients, these fixed costs will weigh heavily on the bottom line.
High Proportion of Unreimbursed Product
A specific data point contradicts the flawless launch narrative: 50% of the newly filled PALSONIFY bottles were from the 'Quickstart' program (free drug). While typical for rare disease launches (average conversion takes ~57 days), it represents significant revenue leakage in the short term. Converting these patients to commercial payers in H1 2026 is critical to hitting consensus revenue estimates.
Pipeline Diversification into Oncology
Crinetics initiated the BRAVESST2 Phase 1/2 trial for CRN09682, validating its proprietary nonpeptide drug conjugate (NDC) platform. This marks a strategic shift from pure endocrinology into GPCR-targeted solid tumors, introducing a high-risk, high-reward technology innovation to the pipeline.
R&D Expense Base Remains Elevated
R&D expense of $85.1M in Q4 was a sequential deceleration from Q3's $90.5M (due to Q3 recognizing specific startup costs), but it represents a 28% YoY increase. With the operationally seamless Phase 2/3 EQUILIBRIUM study for Cushing's Syndrome starting in H1 2026 alongside three ongoing Phase 3 trials, R&D costs will remain a massive drag on cash flow.
Other KPIs
The company ended FY25 with $1.0B in cash and investments. The $380M net proceeds from the January 2026 underwritten public offering pushed this to $1.4B. Management previously noted this provides a cash runway well into 2029, completely insulating the company from near-term capital market volatility.
Crinetics successfully managed its burn, coming in below its previously guided range of $340-$370 million. This demonstrates financial discipline even amid a major commercial ramp-up and multiple Phase 3 trial initiations.
Stable sequentially compared to $52.3M in Q3, but up 90% YoY from $28.2M. The sequential stability shows that the bulk of the initial commercial infrastructure build-out was completed prior to the FDA approval, transitioning now to maintenance and execution.
Guidance
Accelerating. The midpoint of $625M implies a 19% YoY increase compared to FY25's actual operating expenses of $524.5M. This reflects the full-year impact of carrying a commercial sales force and funding four major late-stage clinical trials simultaneously.
Accelerating. Excludes cost of product revenue, stock-based compensation, and depreciation. The midpoint of $500M implies a 17% increase over FY25's non-GAAP actuals of $428.5M.
Key Questions
Quickstart Conversion Dynamics
With 50% of Q4 bottles originating from the Quickstart program, what is the current average time to secure prior authorizations, and what gross-to-net discount should we model as these patients transition to commercial reimbursement?
New vs Switch Patient Mix
During Q3 you mentioned 95% of early prescriptions were 'switch' patients. With 200+ enrollment forms now in hand, how has the mix evolved regarding newly diagnosed treatment-naive patients?
Cushing's Syndrome Trial Design
The Phase 2/3 EQUILIBRIUM study for atumelnant in Cushing's Syndrome is initiating in H1 2026. What specific primary endpoints were agreed upon with the FDA, given the unique mechanism of action?
European Launch Strategy
Following the positive CHMP opinion, what is the timeline for establishing the European commercial footprint, and will you pursue a direct-to-market approach in key countries like Germany or utilize regional partnerships?